Frade-Sosa, Beatriz;
Ponce, Andrés;
Ruiz-Esquide, Virginia;
García-Yébenes, Maria Jesús;
Morlá, Rosa;
Sapena, Nuria;
Ramirez, Julio;
Azuaga, Ana Belen;
Sarmiento, Juan Camilo;
Cañete, Juan D.;
Gomez-Puerta, Jose A.;
Sanmarti, Raimon
High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
Contributor:
Frade-Sosa, Beatriz;
Ponce, Andrés;
Ruiz-Esquide, Virginia;
García-Yébenes, Maria Jesús;
Morlá, Rosa;
Sapena, Nuria;
Ramirez, Julio;
Azuaga, Ana Belen;
Sarmiento, Juan Camilo;
Cañete, Juan D.;
Gomez-Puerta, Jose A.;
Sanmarti, Raimon
Description:
<jats:p>Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (p = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis.</jats:p>